Buccal midazolam for agitation on psychiatric intensive care wards

David Taylor; Chike Okocha; Carol Paton; Shubalade Smith; Anne Connolly

doi:10.1080/13651500802233886

Buccal midazolam for agitation on psychiatric intensive care wards

David Taylor, Chike Okocha, Carol Paton, Shubalade Smith, Anne Connolly

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Midazolam is a benzodiazepine known to be effective as a treatment for status epilepticus and for rapid tranquillisation. Buccal midazolam has recently become available in the UK. We introduced it as a treatment option for rapid tranquillisation on our intensive care wards. Buccal midazolam was found to be effective and well tolerated. Target levels of sedation were achieved in nearly 70% of subjects within half an hour. Activity was evident within 15 minutes. Over-sedation occurred in only one patient at one time point. There were no cases of respiratory depression. Buccal midazolam deserves further investigation as a non-invasive treatment option in rapid tranquillisation.

Original language	English
Pages (from-to)	309-11
Number of pages	3
Journal	International Journal of Psychiatry in Clinical Practice
Volume	12
Issue number	4
DOIs	https://doi.org/10.1080/13651500802233886
Publication status	Published - 2008
Event	International Forum on Mood and Anxiety Disorders - Vienna, Austria Duration: 12 Nov 2008 → 14 Nov 2008

Access to Document

10.1080/13651500802233886

Cite this

@article{2d0ae9bfd75e4e5188c2ca75a888d401,

title = "Buccal midazolam for agitation on psychiatric intensive care wards",

abstract = "Midazolam is a benzodiazepine known to be effective as a treatment for status epilepticus and for rapid tranquillisation. Buccal midazolam has recently become available in the UK. We introduced it as a treatment option for rapid tranquillisation on our intensive care wards. Buccal midazolam was found to be effective and well tolerated. Target levels of sedation were achieved in nearly 70% of subjects within half an hour. Activity was evident within 15 minutes. Over-sedation occurred in only one patient at one time point. There were no cases of respiratory depression. Buccal midazolam deserves further investigation as a non-invasive treatment option in rapid tranquillisation.",

author = "David Taylor and Chike Okocha and Carol Paton and Shubalade Smith and Anne Connolly",

year = "2008",

doi = "10.1080/13651500802233886",

language = "English",

volume = "12",

pages = "309--11",

journal = "International Journal of Psychiatry in Clinical Practice",

issn = "1365-1501",

publisher = "Informa Healthcare",

number = "4",

note = "International Forum on Mood and Anxiety Disorders ; Conference date: 12-11-2008 Through 14-11-2008",

}

TY - JOUR

T1 - Buccal midazolam for agitation on psychiatric intensive care wards

AU - Taylor, David

AU - Okocha, Chike

AU - Paton, Carol

AU - Smith, Shubalade

AU - Connolly, Anne

PY - 2008

Y1 - 2008

N2 - Midazolam is a benzodiazepine known to be effective as a treatment for status epilepticus and for rapid tranquillisation. Buccal midazolam has recently become available in the UK. We introduced it as a treatment option for rapid tranquillisation on our intensive care wards. Buccal midazolam was found to be effective and well tolerated. Target levels of sedation were achieved in nearly 70% of subjects within half an hour. Activity was evident within 15 minutes. Over-sedation occurred in only one patient at one time point. There were no cases of respiratory depression. Buccal midazolam deserves further investigation as a non-invasive treatment option in rapid tranquillisation.

AB - Midazolam is a benzodiazepine known to be effective as a treatment for status epilepticus and for rapid tranquillisation. Buccal midazolam has recently become available in the UK. We introduced it as a treatment option for rapid tranquillisation on our intensive care wards. Buccal midazolam was found to be effective and well tolerated. Target levels of sedation were achieved in nearly 70% of subjects within half an hour. Activity was evident within 15 minutes. Over-sedation occurred in only one patient at one time point. There were no cases of respiratory depression. Buccal midazolam deserves further investigation as a non-invasive treatment option in rapid tranquillisation.

UR - http://www.scopus.com/inward/record.url?scp=55349103054&partnerID=8YFLogxK

U2 - 10.1080/13651500802233886

DO - 10.1080/13651500802233886

M3 - Article

C2 - 24937720

SN - 1365-1501

VL - 12

SP - 309

EP - 311

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

IS - 4

T2 - International Forum on Mood and Anxiety Disorders

Y2 - 12 November 2008 through 14 November 2008

ER -

Buccal midazolam for agitation on psychiatric intensive care wards

Abstract

Access to Document

Other files and links

Fingerprint

Cite this